Immuron Limited American Depositary Shares (IMRN) is a publicly traded Healthcare sector company. As of May 21, 2026, IMRN trades at $0.99 with a market cap of $8.17M and a P/E ratio of 0.00. IMRN moved +0.00% today. Year to date, IMRN is +20.73%; over the trailing twelve months it is -38.51%. Its 52-week range spans $0.68 to $2.87. Rallies surfaces IMRN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Immuron’s Q3 Revenue Rises 16% to AUD 1.5M; Price Target Boosted to $4.00: Emerging Growth Research raised Immuron's 12-month price target to $4.00 and maintained its Buy-Extended rating after 3Q FY2026 revenue rose 16% year-over-year to AUD 1.5 million. Australian sales climbed 15% in AUD, Canadian revenue surged 82% sequentially, and the clinical pipeline advanced two candidates toward Phase 2 trials.
| Metric | Value |
|---|---|
| Price | $0.99 |
| Market Cap | $8.17M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.87 |
| 52-Week Low | $0.68 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
IMRN analyst coverage data. Average price target: $0.00.